Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VBC101

PreclinicalSmall molecule

VVelaVigo Bio Inc

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Participants With Advanced Solid Tumor MalignanciesRecruiting

Participants With Advanced Solid Tumor MalignanciesPreclinical

Recruiting

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Participants With Advanced Solid Tumor Malignancies

NCT07136779

Clinical

Trials by Indication[1]

Participants With Advanced Solid Tumor Malignancies1 trial

PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

Recruiting·VVelaVigo Bio Inc·Preclinical·NCT07136779·310 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VBC101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VBC101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VBC101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VelaVigo Bio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVelaVigo Bio Inc

Related News